PAP
TGTX icon

Persistent Asset Partners’s TG Therapeutics TGTX Stock Holding History

Persistent Asset Partners’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-295
Closed -$5.12K – 211
2024
Q4 		$5.12K Buy
+295
New +$8.47K ﹤0.01% 134

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Persistent Asset Partners's TGTX Position: Q1 2026 in Review

Persistent Asset Partners increased its TG Therapeutics (TGTX) stake by 60% in Q1 2026, buying an estimated $592K and bringing the position to 53,080 shares worth $1.76M. The position accounts for 0.66% of the portfolio, ranked #38.

Persistent Asset Partners first reported a position in TGTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.08M in Q2 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Persistent Asset Partners held 53,080 shares of TG Therapeutics worth $1.76M as of Q1 2026.
  • Persistent Asset Partners bought 19,868 TG Therapeutics shares in Q1 2026, an estimated $592K.
  • TG Therapeutics made up 0.66% of Persistent Asset Partners's portfolio in Q1 2026, its #38 holding.
  • Persistent Asset Partners first reported a position in TG Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Persistent Asset Partners's TG Therapeutics position peaked at $3.08M in Q2 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.